241 related articles for article (PubMed ID: 37324457)
1. RIPK2: a promising target for cancer treatment.
You J; Wang Y; Chen H; Jin F
Front Pharmacol; 2023; 14():1192970. PubMed ID: 37324457
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.
Pham AT; Ghilardi AF; Sun L
Front Pharmacol; 2023; 14():1127722. PubMed ID: 36959850
[TBL] [Abstract][Full Text] [Related]
3. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target.
Rivoal M; Dubuquoy L; Millet R; Leleu-Chavain N
J Med Chem; 2023 Nov; 66(21):14391-14410. PubMed ID: 37857324
[TBL] [Abstract][Full Text] [Related]
4. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.
Honjo H; Watanabe T; Kamata K; Minaga K; Kudo M
Front Pharmacol; 2021; 12():650403. PubMed ID: 33935757
[TBL] [Abstract][Full Text] [Related]
5. Assaying RIPK2 Activation by Complex Formation.
Steinle H; Ellwanger K; Kufer TA
Methods Mol Biol; 2022; 2523():133-150. PubMed ID: 35759195
[TBL] [Abstract][Full Text] [Related]
6. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
7. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.
Cavallari JF; Barra NG; Foley KP; Lee A; Duggan BM; Henriksbo BD; Anhê FF; Ashkar AA; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E579-E585. PubMed ID: 32101030
[TBL] [Abstract][Full Text] [Related]
8. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.
Nikhar S; Siokas I; Schlicher L; Lee S; Gyrd-Hansen M; Degterev A; Cuny GD
Eur J Med Chem; 2021 Apr; 215():113252. PubMed ID: 33601309
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
10. Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway.
Zhang W; Wang Y
Histochem Cell Biol; 2022 Feb; 157(2):173-182. PubMed ID: 34825931
[TBL] [Abstract][Full Text] [Related]
11. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.
Nachbur U; Stafford CA; Bankovacki A; Zhan Y; Lindqvist LM; Fiil BK; Khakham Y; Ko HJ; Sandow JJ; Falk H; Holien JK; Chau D; Hildebrand J; Vince JE; Sharp PP; Webb AI; Jackman KA; Mühlen S; Kennedy CL; Lowes KN; Murphy JM; Gyrd-Hansen M; Parker MW; Hartland EL; Lew AM; Huang DC; Lessene G; Silke J
Nat Commun; 2015 Mar; 6():6442. PubMed ID: 25778803
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Duggan BM; Foley KP; Henriksbo BD; Cavallari JF; Tamrakar AK; Schertzer JD
Sci Rep; 2017 May; 7(1):1578. PubMed ID: 28484277
[TBL] [Abstract][Full Text] [Related]
13. A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.
Heim VJ; Dagley LF; Stafford CA; Hansen FM; Clayer E; Bankovacki A; Webb AI; Lucet IS; Silke J; Nachbur U
EMBO Rep; 2020 Nov; 21(11):e50400. PubMed ID: 32954645
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 and erlin proteins differentially interact with RIPK2 complexes.
Steinle H; Ellwanger K; Mirza N; Briese S; Kienes I; Pfannstiel J; Kufer TA
J Cell Sci; 2021 Jun; 134(12):. PubMed ID: 34152391
[TBL] [Abstract][Full Text] [Related]
15. Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.
He X; Da Ros S; Nelson J; Zhu X; Jiang T; Okram B; Jiang S; Michellys PY; Iskandar M; Espinola S; Jia Y; Bursulaya B; Kreusch A; Gao MY; Spraggon G; Baaten J; Clemmer L; Meeusen S; Huang D; Hill R; Nguyen-Tran V; Fathman J; Liu B; Tuntland T; Gordon P; Hollenbeck T; Ng K; Shi J; Bordone L; Liu H
ACS Med Chem Lett; 2017 Oct; 8(10):1048-1053. PubMed ID: 29057049
[TBL] [Abstract][Full Text] [Related]
16. RIPK2 inhibitors for disease therapy: Current status and perspectives.
Tian E; Zhou C; Quan S; Su C; Zhang G; Yu Q; Li J; Zhang J
Eur J Med Chem; 2023 Nov; 259():115683. PubMed ID: 37531744
[TBL] [Abstract][Full Text] [Related]
17. RIPK2 NODs to XIAP and IBD.
Topal Y; Gyrd-Hansen M
Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
[TBL] [Abstract][Full Text] [Related]
18. Expression and activity of NOD1 and NOD2/RIPK2 signalling in mononuclear cells from patients with rheumatoid arthritis.
Franca R; Vieira SM; Talbot J; Peres RS; Pinto LG; Zamboni DS; Louzada-Junior P; Cunha FQ; Cunha TM
Scand J Rheumatol; 2016 Jan; 45(1):8-12. PubMed ID: 26202066
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
20. Joint NOD2/RIPK2 signaling regulates IL-17 axis and contributes to the development of experimental arthritis.
Vieira SM; Cunha TM; França RF; Pinto LG; Talbot J; Turato WM; Lemos HP; Lima JB; Verri WA; Almeida SC; Ferreira SH; Louzada-Junior P; Zamboni DS; Cunha FQ
J Immunol; 2012 May; 188(10):5116-22. PubMed ID: 22491249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
